1. Home
  2. OCSL vs CGEM Comparison

OCSL vs CGEM Comparison

Compare OCSL & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oaktree Specialty Lending Corporation

OCSL

Oaktree Specialty Lending Corporation

HOLD

Current Price

$11.85

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$15.66

Market Cap

904.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OCSL
CGEM
Founded
2007
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
904.7M
IPO Year
2007
2020

Fundamental Metrics

Financial Performance
Metric
OCSL
CGEM
Price
$11.85
$15.66
Analyst Decision
Hold
Strong Buy
Analyst Count
4
8
Target Price
$12.63
$30.13
AVG Volume (30 Days)
742.0K
908.9K
Earning Date
05-05-2026
05-11-2026
Dividend Yield
12.73%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.31
$5.20
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.63
$5.68
52 Week High
$14.77
$16.74

Technical Indicators

Market Signals
Indicator
OCSL
CGEM
Relative Strength Index (RSI) 43.79 57.94
Support Level $11.01 $11.92
Resistance Level $13.89 $16.21
Average True Range (ATR) 0.24 0.98
MACD -0.05 -0.01
Stochastic Oscillator 27.21 69.46

Price Performance

Historical Comparison
OCSL
CGEM

About OCSL Oaktree Specialty Lending Corporation

Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies and manages the business on a consolidated basis.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: